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Abstract
Background:  In recent years encouraging progress has been made in developing vaccine
treatments for cancer, particularly with melanoma. However, the overall rate of clinically significant
results has remained low. The present research used microarray datasets from previous
investigations to examine gene expression patterns in cancer cell lines with the goal of better
understanding the tumor microenvironment.
Methods: Principal Components Analyses with Promax rotational transformations were carried
out with 90 cancer cell lines from 3 microarray datasets, which had been made available on the
internet as supplementary information from prior publications.
Results: In each of the analyses a well defined melanoma component was identified that contained
a gene coding for the enzyme, glutaminyl cyclase, which was as highly expressed as genes from a
variety of well established biomarkers for melanoma, such as MAGE-3 and MART-1, which have
frequently been used in clinical trials of melanoma vaccines.
Conclusion: Since glutaminyl cyclase converts glutamine and glutamic acid into a pyroglutamic
form, it may interfere with the tumor destructive process of vaccines using peptides having
glutamine or glutamic acid at their N-terminals. Finding ways of inhibiting the activity of glutaminyl
cyclase in the tumor microenvironment may help to increase the effectiveness of some melanoma
vaccines.
Background
In recent decades considerable progress has been made in
developing methods which use the immune system to
treat cancer. One particularly noteworthy series of events
was the discovery of the first genes encoding human
tumor antigens recognized by cytolytic T lymphocytes
(CTLs) [1-3]. Since then, dozens of other antigen genes
have been identified [4], many of which contain several
short sequences of DNA, coding for peptides called
"epitopes." When epitopes are bound by members of the
human leukocyte antigen (HLA) family, presented on the
tumor cell surface, and recognized by CTLs; destruction of
the tumor cell tends to occur. Scientists have become so
adept at using such methods for reproducibly destroying
tumor cells in the laboratory that many small scale clinical
vaccine trials have been carried out [5]. Unfortunately,
although there have been reports of some dramatic remis-
sions, the overall degree of successful therapy has
remained low [6].
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Explanations for the difficulty in translating findings from
the laboratory to the clinic in the field of tumor antigen
(TA) specific immunotherapy have focussed upon a vari-
ety of factors, one of which has been the importance of
better understanding the tumor microenvironment [7]. In
this regard, it has been suggested that breakthroughs in
the development of microarray technology may be able to
help overcome tumor resistance to effective vaccine
responses [5,8].
The present report is of a retrospective microarray
datamining study looking for information relevant to the
tumor microenvironment in TA specific immunotherapy.
Methods
The first dataset analysed in the current research was pub-
lished in a study by Ross et al [9] using the National Can-
cer Institute (NCI) group of 60 cancer cell lines from 9
different tissues of origin: melanoma, colon, renal, breast,
CNS, leukemia, prostate, lung, and ovarian. For each of
the NCI60 cell lines, expression levels of approximately
8000 genes were obtained from a microarray upon which
9706 cDNAs had been physically deposited. This dataset
is available at the Genomics and Bioinformatics Group
Microarray Datasets website [10].
The second dataset was collected by Staunton et al [11]
using the NCI60 cell lines and an Affymetrix microarray,
upon which short (25-mer) oglionucleoties had been
directly synthesized. Using this form of microarray plat-
form 7130 gene expression levels were measured. The raw
data has been deposited at the Genomics and Bioinfor-
matics Group Microarray Datasets website [12].
The third dataset used here was published in conjunction
with a paper by Györffy et al [13] using an Affymetrix
HGU133 microarray chip containing 42297 estimates of
gene expression levels. This study utilized 30 cancer cell
lines from 9 different types of human tissue: breast, liver,
lung, melanoma, ovarian, pancreas, colon, gastric and
prostate. The microarray raw dataset was made available
in supplementary Table 1 published with the article.
The primary method used in the present research was the
multivariate statistical technique of principal components
analysis (PCA), previously utilized with microarray data
in a study by Crescenzi and Giuliani [14]. However,
unlike the Crescenzi and Giuliani research, in which
cDNAs with values for all 60 cell lines were used, the
present PCA was carried out after replacing any missing
values with the mean for each cell line. This meant that,
instead of using 1416 cDNAs, there were 9706 values
included in the PCA. Another important difference was
that, following the main principal components extraction,
Promax rotational transformations were performed [15].
These alternative, complementary procedures were under-
taken to see if PCA could produce results in addition to
the interesting findings obtained in earlier research [14].
Additional analyses were carried out using: (a) Pearson
product-moment correlation coefficients, (b) linear dis-
criminant analysis, and (c) unpaired two-tailed Student t
tests for the difference between means from independent
samples. Prior to each t test, F ratios were calculated to
ascertain whether to assume equality of variances.
All analyses were performed with SPSS for Windows XP
(Version 12.0) using default values for each procedure
unless otherwise indicated. Prior to the PCA, the NCI60
Affymetrix microarray expression estimates were con-
verted to standardized z-scores.
Results
Ross et al cDNA microaarray data
Pearson product-moment correlation coefficients were
calculated between the cell lines, and then eigenvalues for
the 60 × 60 correlation matrix were calculated. A scree test
[14,16,17], presented in Figure 1, was performed using
the eigenvalues plot. The scree results indicated that it
would be appropriate to extract 9 components. Following
extraction of 9 principal components, Promax rotations
Scree test for the Ross et al dataset Figure 1
Scree test for the Ross et al dataset. Eigenvalues from 
the 60 × 60 cell line correlation matrix showed that, begin-
ning with the break in the plot after component 9, a straight 
scree line could be fitted to the remaining values. Such a find-
ing suggests that the eigenvalues after component 9 repre-
sent only error variance. The term "scree" was borrowed 
from geology where it refers to debris (i.e. error) that has 
fallen to the base of a mountain. Note that for clarity of pres-
entation, the first eigenvalue of 13.787 was not plotted.
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were carried out. As may be seen in the Promax compo-
nent pattern loading values presented in Table 1 (see
Additional file 1), there were 68% of the loadings within
the +/-.10 hyperplane, which indicated that a high degree
of simple structure had been achieved [17-19]. In addi-
tion, it may be seen in Table 1 (see Additional file 1) that
Component #1 consisted of the melanoma cell lines:
MALME3M, SLMEL2, SKMEL5, SKMEL28, M14, UACC62
and UACC257 together with MDAMB435 and MDAN.
This group of cell lines is identical with the Melanoma
Cluster found previously by hierarchical clustering in two
separate research reports (see Figure 1 of Ross et al [9] and
cluster 3 in Figure 3 of Crescenzi and Giuliani [14]).
It should be noted that there is evidence the cell lines,
MDAMB435 and MDAN (derived from the same patient),
originally believed to be of breast cancer in origin, may
have resulted from melanoma metastasis [9]. At the same
time, the allegedly melanoma cell line, LOXIMVI, which
had previously fallen outside of the Melanoma Cluster
[9,14], also did not appear in the present Melanoma
Component. Because of these questions about the cancer
type of these three cell lines, as a conservative measure,
their scores were not included in further statistical analy-
ses.
In order to identify the most highly expressed genes in the
cell lines comprising the Melanoma Component, regres-
sion scores were calculated for each of the 9706 cDNAs.
The 26 highest scoring genes of the Melanoma Compo-
nent (together with the component regression score for
each gene) are listed in Table 2 (see Additional file 2), fol-
lowed by the 26 genes found by Ross et al within their
Melanoma Cluster. In Table 2 (see Additional file 2) it
may be seen that 14 of the genes identified by Ross et al
were among the highest scoring in the present Melanoma
Component. From the 14 genes falling in both the Ross et
al and the present melanoma group, several genes were
chosen for presentation in Figure 2, these genes were:
Melanoma Antigen recognized by T-cells (MART1), Tyro-
sinase (TYR), Tyrosinase Related Protein 1 (TYRP1) and
Tyrosinase Related Protein 2 (TYRP2). These four genes
were selected because they are well known biomarkers for
melanoma and have been utilized as epitopes in tumor
immunotherapy [5]. Also presented in Figure 2 was the
gene, Glutaminyl Cyclase (QPCT). The reason for select-
ing QPCT was that, as may be seen in later subsections, it
was found to be highly expressed in two other microarray
datasets.
Next, to determine how a combination (and not only a
gene-by-gene analysis) of the selected genes perform on
the melanoma identification, a linear discriminant analy-
sis [20] was performed using MART1, TYR, TYRP1, TYRP2
and QPCT as independent variables and melanoma vs
non-melanoma PCA scores as the grouping variable. It
was found that the overall gene combination was related
to the melanoma distinction (Wilks Lambda = .057, p <
.001) with the standardized canonical discriminant func-
tion coefficients being MART1 = .267, TYR = .420, TYRP1
= .361, TYRP2 = .595, and QPCT = .808.
Staunton et al Affymetrix microaarray data
As with the cDNA analysis, a scree test with the eigenval-
ues from the 60 × 60 NCI Affymetrix correlation matrix
indicated that 9 components should be extracted (Figure
3). PCA was performed on the NCI60 Affymetrix gene
expression estimates. The PCA produced results that were
highly similar to those obtained with the cDNA values
analysed in the original Ross et al study [9]. It was found
that PROMAX rotations (with the maximum iterations for
convergence parameter set at 50 instead of the default
value of 25) resulted in a readily identifiable Melanoma
Component (component pattern loading values are pre-
sented in Table 3 – see Additional file 3) made up of the
Highly expressed genes within the Ross et al Melanoma  Component Figure 2
Highly expressed genes within the Ross et al 
Melanoma Component. Gene expression levels of 5 
genes within each of the 7 cell lines in the Ross et al cDNA 
Melanoma Component. Measurements were log ratios 
between the gene expression level of each cell line and a ref-
erence sample of 12 of the 60 tumor cell lines. Further 
details may be found in the original Ross et al publication. 
The means for each gene for the non-melanoma cell lines 
(followed by the Student t test significances for the mean dif-
ference between melanoma and non-melanoma cell lines) 
were as follows: QPCT -.514 (p < .001), MART1 -.055 (p = 
.001), TYR -.031 (P < .001), TYRP1 -.449 (P < .001), and 
TYRP2 -.041 (p < .001). It may be seen that the means of the 
non-melanoma cell lines were all very close to zero, and 
therefore were not plotted simply for greater clarity of pres-
entation.
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cell lines, MALME3M, SLMEL2, SKMEL5, SKMEL28, M14,
UACC62 and UACC257.
When component scores were calculated for each of the
genes on the microarray, the enzyme QPCT again was
found to be as highly expressed (see Figure 4) as some
well known proteins used in melanoma immunotherapy
[5]: MART1, Melanoma Antigen 1 (MAGE1) and
Melanoma Antigen 3 (MAGE3).
Combined Ross et al and Staunton et al data analysis
In order to show the effective consistence of the Staunton
et al Melanoma Component (shown in Table 3 – see Addi-
tional file 3) with the previously identified Melanoma
Component from the Ross et al data (depicted in Table 1
– see Additional file 1), a Pearson Correlation Coefficient
was calculated between the loading values. The obtained
value of .905 (p < .001) supported a hypothesis of identity
between these component patterns.
Györffy et al Affymetrix microarray data
As with the other 2 analyses, PCA results with the Affyme-
trix HGU133 microarray chip produced results that
matched well with previous findings. A scree test indi-
cated that 9 components should be extracted (Figure 5).
Following components extraction and Promax rotations,
one of the 9 components clearly corresponded to the
Melanoma Cluster found in the original Györffy et al
study [13]. The Melanoma Component (component pat-
tern loading values are presented in Table 4 – see Addi-
tional file 4) was composed primarily of the melanoma
cell lines ME43, MEWO, A375, SKMEL13 and SKMEL19.
One lung cell line, COLO699, loaded significantly on the
Melanoma Component, and one melanoma cell line,
C8161, did not load. However, both of these findings also
occurred in the hierarchical cluster analysis of the Györffy
et al study (see their Figure 5) [13].
Interestingly, the QPCT enzyme again was expressed at a
level similar to well established antigens used in
melanoma vaccines [5]: MART1, MAGE3 and TYRP2 (Fig-
ure 6).
Discussion
Prior to the present findings there had been several indi-
cations that the gene coding for glutaminyl cyclase tends
to be highly expressed in melanoma. In an exploratory
microarray study aimed at identifying potential immuno-
Highly expressed genes within the Staunton et al Melanoma  Component Figure 4
Highly expressed genes within the Staunton et al 
Melanoma Component. Gene expression levels of 4 
genes within each of the 7 cell lines in the Staunton et al 
Affymetrix Melanoma Component together with the mean 
expression levels for the combined non-melanoma cell lines. 
The expression values were average intensity difference units 
determined with Affymetrix GENECHIP software that 
assigned a value of 100 to all expression measurements of 
less than 100 units. Further details may be found in the 
Staunton et al publication. The Student t test significance lev-
els for each gene, calculated between the melanoma and the 
non-melanoma cell lines, were as follows: QPCT (p = .033), 
MART1 (p = .012), MAGE1 (p = .019) and MAGE3 (p = 
.024). Note that for clarity of presentation, this figure used 
expression average intensity difference units, as they were 
prior to conversion to the standardized z-scores that were 
used in the PCA and t test calculations.
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Scree test for the Staunton et al dataset Figure 3
Scree test for the Staunton et al dataset. Eigenvalues 
from the 60 × 60 cell line correlation matrix showed that, 
beginning with the break in the plot after component 9, a 
straight scree line could be fitted to the remaining values. 
Such a finding suggests that the eigenvalues after component 
9 represent only error variance. Note that for clarity of pres-
entation, the first eigenvalue of 51.392 was not plotted.
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logical targets in tumor microenvirnoments, Wang et al
[21] published an additional file listing 2044 clones
which appeared to be upregulated in metastatic cutaneous
melanoma. Included in this list of cDNA clones was
glutaminyl cyclase.
In another study, employing the high throughput method
of Serial Analysis of Gene Expression to survey the gene
expression patterns of melanoma tumor samples, Weera-
ratna  et al [22] identified glutaminyl cyclase as being
among those most abundantly expressed [see their Figure
1 (c)].
Consequently, when combined with the present findings,
there is now evidence from a variety of sources supporting
the notion that glutaminyl cyclase tends to be highly
expressed in melanoma.
Evidence about the potential significance of this finding
for immunological treatment of cancer comes from sev-
eral sources. Firstly, it is interesting to note that several
highly researched epitopes, such as MAGE3 (EVD-
PIGHLY) and the synthetic MART1 (ELAGIGILTV), which
are among those having produced the most clinically
interesting results [23-26], have an E at their N-terminal.
Secondly, it has been shown that the main function of
glutaminyl cyclase is to accelerate the transformation of
glutamine (Q) or glutamic acid (E) into pyroglutamic acid
(pE) [27,28]. Thirdly, when either Q or E occur at the N
terminal of an epitope, their cyclic transformation to pE
has been shown to decrease the affinity with which the
peptide will bind with HLA molecules [29,30]. Hence,
high levels of glutaminyl cyclase within melanoma cells
may interfere with the avidity with which T cells recognize
and destroy tumors.
The plausibility of such a scenario is increased by knowl-
edge that the generation of antigenic peptides is a multi-
step process. Part of this process takes place in the
endoplasmic reticulum (ER), and the glutaminyl cyclase
gene codes for an ER targeting signal [31].
Should laboratory research confirm the present microar-
ray-derived indication of QPCT activity within the
melanoma tumor microenvironment, attention may be
focused upon finding ways to overcome QPCT interfer-
ence. In this regard it is interesting to note that potent new
inhibitors have been discovered recently for QPCT [32].
However, application of such inhibitors in a clinical set-
ting is likely to present difficulties, because QPCT plays a
significant role in many normal physiological processes,
such as influencing the bioactivity of hormones like gona-
dotropin-releasing hormone and thyrotropin-releasing
hormone [33]. It is also noteworthy that QPCT may be
Highly expressed genes within the Györffy et al Melanoma  Component Figure 6
Highly expressed genes within the Györffy et al 
Melanoma Component. Gene expression levels of 4 
genes within each of the 5 cell lines in the Györffy et al 
Melanoma Component together with the mean expression 
levels for the combined non-melanoma cell lines. The expres-
sion values were average intensity difference units deter-
mined with Affymetrix MAS 5.0 software. Further details may 
be found in the Györffy et al publication. The Student t test 
significance levels for each gene, calculated between the 
melanoma and the non-melanoma cell lines, were as follows: 
QPCT (p < .001), MART1 (p = .010), MAGE3 (p < .001) and 
TYRP2 (p < .001).
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Scree test for the Györffy et al Affymetrix dataset. 
Eigenvalues from the 30 × 30 cell line correlation matrix 
showed that, beginning with the break in the plot after com-
ponent 9, a straight scree line could be fitted to the remain-
ing values. Such a finding suggests that the eigenvalues after 
component 9 represent only error variance. Note that for 
clarity of presentation, the first eigenvalue of 27.020 was not 
plotted.
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essential for the activity of monocyte chemotactic protein
2 (MCF-2), since MCF-2 is practically inactive without a
pE at its N-terminal [34]. Perhaps the development of tis-
sue specific inhibitors could help to overcome problems
due to the widespread activity of glutaminyl cyclase [35].
Another possible difficulty is that there is some evidence
that glutaminyl cyclase, like MART-1, TYR, and TYRP2,
may be highly expressed in normal melanocytes as well as
in melanoma (see Table 1 of Dooley et al [36]). Further
research is needed to find ways to overcome such poten-
tial problems in translating results from the present basic
research into clinical immunotherapy.
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